KeyCorp Trims LifeMD (NASDAQ:LFMD) Target Price to $10.00

LifeMD (NASDAQ:LFMD) had its target price lowered by KeyCorp from $12.00 to $10.00 in a report released on Thursday morning, Benzinga reports. KeyCorp currently has an overweight rating on the stock.

Several other research firms have also issued reports on LFMD. BTIG Research increased their target price on LifeMD from $13.00 to $14.00 and gave the stock a buy rating in a report on Tuesday, April 23rd. HC Wainwright reissued a buy rating and set a $12.00 target price on shares of LifeMD in a report on Friday, May 10th. Cantor Fitzgerald increased their target price on LifeMD from $13.00 to $15.00 and gave the stock an overweight rating in a report on Thursday, May 9th. Finally, B. Riley reissued a buy rating and set a $12.00 target price on shares of LifeMD in a report on Tuesday, May 21st. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, LifeMD has an average rating of Buy and a consensus price target of $12.17.

LifeMD Stock Down 1.4 %

LFMD stock opened at $6.17 on Thursday. The company has a debt-to-equity ratio of 10.83, a current ratio of 0.99 and a quick ratio of 0.94. The stock has a market capitalization of $257.66 million, a price-to-earnings ratio of -8.34 and a beta of 1.24. The business’s fifty day moving average price is $7.85 and its two-hundred day moving average price is $8.14. LifeMD has a fifty-two week low of $3.31 and a fifty-two week high of $12.88.

LifeMD (NASDAQ:LFMD) last posted its quarterly earnings data on Wednesday, May 8th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.06). The business had revenue of $44.14 million during the quarter, compared to analysts’ expectations of $42.66 million. On average, equities analysts anticipate that LifeMD will post -0.25 earnings per share for the current year.

Institutional Trading of LifeMD

Several large investors have recently bought and sold shares of LFMD. Tower Research Capital LLC TRC boosted its stake in LifeMD by 266.3% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,605 shares of the company’s stock valued at $38,000 after buying an additional 3,348 shares in the last quarter. EntryPoint Capital LLC acquired a new stake in LifeMD in the first quarter valued at about $89,000. Thompson Davis & CO. Inc. acquired a new stake in LifeMD in the fourth quarter valued at about $117,000. Russell Investments Group Ltd. acquired a new stake in LifeMD in the fourth quarter valued at about $153,000. Finally, Raymond James Financial Services Advisors Inc. acquired a new stake in LifeMD in the fourth quarter valued at about $173,000. 35.52% of the stock is owned by institutional investors and hedge funds.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.